The document discusses strategies to increase acquisition and adherence for the drug Arimidex among breast cancer patients. It analyzes the patient journey and identifies opportunities to shift messaging from treatment-focused to promoting long-term adherence. The proposed program involves amplifying support tools and celebrating patients' 1,825 day journey to increase motivation and positive engagement with the drug. Success will be measured through prescription data, website usage, and brand tracking over 5 years.